Cargando…
Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model
BACKGROUND: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of the neurofibromin gene (NF1(+/−)). Even though approximately 40–60% of children with NF1 meet the criteria for attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if...
Autores principales: | Lukkes, J. L., Drozd, H. P., Fitz, S. D., Molosh, A. I., Clapp, D. W., Shekhar, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961243/ https://www.ncbi.nlm.nih.gov/pubmed/31941438 http://dx.doi.org/10.1186/s11689-019-9304-y |
Ejemplares similares
-
The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Sagvolden, Terje
Publicado: (2006) -
ADHD-hyperactive/impulsive subtype in adults
por: Gibbins, Christopher, et al.
Publicado: (2010) -
Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008) -
Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
por: Ota, Toyosaku, et al.
Publicado: (2021) -
Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)